Xencor, Inc. (XNCR)
NASDAQ: XNCR · Real-Time Price · USD
21.57
0.00 (0.00%)
Oct 29, 2024, 4:00 PM EDT - Market closed
Xencor Revenue
Xencor had revenue of $16.96M in the quarter ending June 30, 2024, a decrease of -62.74%. This brings the company's revenue in the last twelve months to $133.62M, up 17.84% year-over-year. In the year 2023, Xencor had annual revenue of $168.34M with 2.28% growth.
Revenue (ttm)
$133.62M
Revenue Growth
+17.84%
P/S Ratio
9.89
Revenue / Employee
$477,207
Employees
280
Market Cap
1.51B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 168.34M | 3.76M | 2.28% |
Dec 31, 2022 | 164.58M | -110.53M | -40.18% |
Dec 31, 2021 | 275.11M | 152.42M | 124.23% |
Dec 31, 2020 | 122.69M | -34.01M | -21.70% |
Dec 31, 2019 | 156.70M | 116.10M | 285.93% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AMN Healthcare Services | 3.23B |
Teladoc Health | 2.61B |
Integra LifeSciences Holdings | 1.57B |
InMode | 416.63M |
STAAR Surgical Company | 332.94M |
Dynavax Technologies | 249.69M |
Arcus Biosciences | 247.00M |
Tarsus Pharmaceuticals | 83.37M |
XNCR News
- 19 days ago - Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases - Business Wire
- 25 days ago - Xencor Announces Upcoming Change to Board of Directors - Business Wire
- 6 weeks ago - Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - Business Wire
- 6 weeks ago - Xencor: Vudalimab Development Along With Hidden Gem Candidate - Seeking Alpha
- 6 weeks ago - Xencor Announces Pricing of $175 Million Public Offering of Common Stock - Business Wire
- 7 weeks ago - Xencor Announces Proposed Public Offering of Common Stock - Business Wire
- 7 weeks ago - Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs - Business Wire
- 7 weeks ago - Xencor to Host Research & Development Webcast and Conference Call on Monday, September 9, 2024 - Business Wire